Table III.
Encounters for ocular surface disorders
| History of atopic dermatitis | History of asthma only | All patients | |
|---|---|---|---|
| Encounter for ocular surface disorder before starting dupilumab, n (%) | 158 (8.7) | 22 (17.1) | 201 (9.4) |
| Conjunctivitis | |||
| Atopic conjunctivitis (H10.1x), n (%) | 75 (4.1) | 14 (10.9) | 99 (4.6) |
| All other conjunctivitis, n (%) | 5 (0.3) | 0 (0) | 7 (0.3) |
| Both, n (%) | 3 (0.2) | 0 (0) | 3 (0.1) |
| Dry eye, n (%) | 86 (4.7) | 8 (6.2) | 103 (4.8) |
| Encounter for ocular surface disorder after starting dupilumab, n (%) | 213 (11.7) | 24 (18.6) | 255 (11.9) |
| Conjunctivitis | |||
| Atopic conjunctivitis (H10.1x), n (%) | 79 (4.4) | 9 (7.0) | 97 (4.5) |
| All other conjunctivitis, n (%) | 35 (1.9) | 1 (0.8) | 38 (1.8) |
| Both, n (%) | 6 (0.3) | 0 (0) | 7 (0.3) |
| Dry eye, n (%) | 111 (6.1) | 16 (12.4) | 133 (6.2) |
| Time from start of dupilumab to encounter for ocular surface disorder, days, median (IQR) | 71 (44-121) | 62 (20-91) | 71 (42-116) |
| Discontinued dupilumab within 45 days of encounter, n (%) | 31 (14.6) | 2 (8.3) | 36 (14.1) |
| Encounter for ocular surface disorder after starting dupilumab among those without a history of ocular surface disorder in the 6 months prior to starting dupilumab, n (%) | 159 (9.6) | 14 (13.1) | 137 (7.9) |
| Conjunctivitis | |||
| Atopic conjunctivitis (H10.1x), n (%) | 44 (2.4) | 5 (3.9) | 51 (2.4) |
| All other conjunctivitis, n (%) | 33 (1.8) | 1 (0.8) | 36 (1.7) |
| Both, n (%) | 5 (0.3) | 0 (0) | 5 (0.2) |
| Dry eye, n (%) | 88 (5.3) | 9 (8.4) | 101 (5.2) |
| Time from start of dupilumab to encounter for ocular surface disorder, days, median (IQR) | 76 (49-124) | 62 (23-92) | 74 (49-120) |
| Discontinued dupilumab within 45 days of encounter, n (%) | 22 (13.8) | 2 (14.3) | 26 (14.4) |
| Encounter for ocular surface disorder with an ophthalmologist before starting dupilumab, n (%) | 57 (3.1) | 4 (3.1) | 66 (3.1) |
| Conjunctivitis | |||
| Atopic conjunctivitis (H10.1x), n (%) | 13 (0.7) | 1 (0.8) | 14 (0.7) |
| All other conjunctivitis, n (%) | 0 (0) | 0 (0) | 0 (0) |
| Both, n (%) | 0 (0) | 0 (0) | 0 (0) |
| Dry eye, n (%) | 45 (2.5) | 3 (2.3) | 53 (2.5) |
| Encounter for ocular surface disorder with an ophthalmologist after starting dupilumab, n (%) | 81 (4.5) | 12 (9.3) | 98 (4.6) |
| Conjunctivitis | |||
| Atopic conjunctivitis (H10.1x), n (%) | 19 (1.0) | 2 (1.6) | 22 (1) |
| All other conjunctivitis, n (%) | 2 (0.1) | 0 (0) | 2 (0.1) |
| Both, n (%) | 0 (0) | 0 (0) | 0 (0) |
| Dry eye, n (%) | 63 (3.5) | 10 (7.8) | 77 (3.6) |
| Encounter for ocular surface disorder with an ophthalmologist after starting dupilumab among those without a history of ocular surface disorder in the 6 months prior to starting dupilumab, n (%) | 67 (3.8) | 9 (7.2) | 79 (3.8) |
| Conjunctivitis | |||
| Atopic conjunctivitis (H10.1x), n (%) | 18 (1.0) | 2 (1.6) | 21 (1) |
| All other conjunctivitis, n (%) | 2 (0.1) | 0 (0) | 2 (0.1) |
| Both, n (%) | 0 (0) | 0 (0) | 0 (0) |
| Dry eye, n (%) | 50 (2.8) | 7 (5.6) | 59 (2.8) |
IQR, Interquartile range.